Vertanical’s VER-01 Outperforms Opioids in Phase III Pain Trials

Vertanical’s cannabis-based pain reliever, VER-01, has demonstrated superior efficacy and safety compared to opioids in the Phase III ELEVATE study (NCT05610813). Among 384 patients, those receiving VER-01 experienced four times lower risk of constipation and were three times less likely to use laxatives than patients on opioids. VER-01 also provided greater pain relief and improved sleep quality over six months, with benefits most pronounced in patients with neuropathic or severe pain.

In a separate Phase III trial (NCT04940741) for chronic lower back pain (CLBP) involving 820 patients, VER-01 significantly reduced pain versus placebo, with a 1.9-point reduction on the 0–10 pain scale at 12 weeks, sustained to 2.9 points over 12 months. Patients also reported better sleep and physical function. VER-01 was generally well tolerated, with mild-to-moderate adverse events mainly during the titration phase. These findings suggest VER-01 could provide effective, non-opioid pain relief, addressing key safety challenges of current therapies.

06-10-2025